Recently, we reported that downregulation of the transcription factor interferon regulatory factor-4 (IRF4) improved antigen sensitivity which enabled CAR T cells to target antigenlow pancreatic cancer cells that are not recognized by CAR T cells with physiological IRF4 levels (48). This evidence concerns the gene IRF4 and pancreatic neoplasm.